| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 化学合成药(元) | 136,834,133.49 | - | 217,784,715.06 | - | 231,344,550.42 |
| 内部抵销(元) | -72,473,524.20 | - | -340,229,834.24 | - | -256,219,492.46 |
| 天然植物药系列(元) | 146,664,624.80 | - | 1,366,452,142.97 | - | 1,500,080,131.58 |
| 外购药品及医疗器械(元) | 1,408,207,239.34 | - | 1,899,906,479.03 | - | 2,011,069,181.53 |
| 妇科(元) | - | 304,232,173.09 | - | 401,178,109.52 | - |
| 骨科系列(元) | - | 108,023,597.16 | - | 102,927,847.22 | - |
| 抗疟疾类(元) | - | 90,451,752.53 | - | 133,264,818.52 | - |
| 消化系统(元) | - | 314,477,435.56 | - | 548,614,861.01 | - |
| 心脑血管疾病治疗领域(元) | - | 1,730,917,913.17 | - | 2,195,100,115.77 | - |
| 药品批发与零售(元) | - | 3,270,458,849.84 | - | 3,655,093,777.41 | - |
| 其他(元) | 22,802,660.66 | 453,274,906.97 | 206,509,992.08 | 923,338,731.64 | 66,283,851.22 |
| 营业成本(元) | |||||
| 化学合成药(元) | 59,411,848.74 | - | 75,362,896.96 | - | 88,943,757.98 |
| 内部抵销(元) | -65,196,973.54 | - | -330,519,351.09 | - | -212,141,206.30 |
| 天然植物药系列(元) | 76,570,510.32 | - | 397,527,369.61 | - | 443,547,743.40 |
| 外购药品及医疗器械(元) | 1,242,728,478.51 | - | 1,678,174,469.43 | - | 1,724,893,502.59 |
| 妇科(元) | - | 127,811,754.95 | - | 176,913,615.61 | - |
| 骨科系列(元) | - | 20,688,569.64 | - | 24,757,044.46 | - |
| 抗疟疾类(元) | - | 54,253,429.27 | - | 99,595,194.17 | - |
| 消化系统(元) | - | 104,315,724.38 | - | 173,468,901.93 | - |
| 心脑血管疾病治疗领域(元) | - | 381,446,902.36 | - | 494,307,735.18 | - |
| 药品批发与零售(元) | - | 2,841,735,717.41 | - | 3,073,928,623.45 | - |
| 其他(元) | 12,427,496.13 | 262,630,105.80 | 194,811,769.43 | 355,070,514.79 | 47,747,043.17 |
| 毛利(元) | |||||
| 化学合成药(元) | 77,422,284.75 | - | 142,421,818.10 | - | 142,400,792.44 |
| 内部抵销(元) | -7,276,550.66 | - | -9,710,483.15 | - | -44,078,286.16 |
| 天然植物药系列(元) | 70,094,114.48 | - | 968,924,773.36 | - | 1,056,532,388.18 |
| 外购药品及医疗器械(元) | 165,478,760.83 | - | 221,732,009.60 | - | 286,175,678.94 |
| 妇科(元) | - | 176,420,418.14 | - | 224,264,493.91 | - |
| 骨科系列(元) | - | 87,335,027.52 | - | 78,170,802.76 | - |
| 抗疟疾类(元) | - | 36,198,323.26 | - | 33,669,624.35 | - |
| 消化系统(元) | - | 210,161,711.18 | - | 375,145,959.08 | - |
| 心脑血管疾病治疗领域(元) | - | 1,349,471,010.81 | - | 1,700,792,380.59 | - |
| 药品批发与零售(元) | - | 428,723,132.43 | - | 581,165,153.96 | - |
| 其他(元) | 10,375,164.53 | 190,644,801.17 | 11,698,222.65 | 568,268,216.85 | 18,536,808.05 |
| 毛利率(%) | |||||
| 化学合成药(%) | 56.58 | - | 65.40 | - | 61.55 |
| 内部抵销(%) | 10.04 | - | 2.85 | - | 17.20 |
| 天然植物药系列(%) | 47.79 | - | 70.91 | - | 70.43 |
| 外购药品及医疗器械(%) | 11.75 | - | 11.67 | - | 14.23 |
| 妇科(%) | - | 57.99 | - | 55.90 | - |
| 骨科系列(%) | - | 80.85 | - | 75.95 | - |
| 抗疟疾类(%) | - | 40.02 | - | 25.27 | - |
| 消化系统(%) | - | 66.83 | - | 68.38 | - |
| 心脑血管疾病治疗领域(%) | - | 77.96 | - | 77.48 | - |
| 药品批发与零售(%) | - | 13.11 | - | 15.90 | - |
| 其他(%) | 45.50 | 42.06 | 5.66 | 61.54 | 27.97 |
| 收入构成(%) | |||||
| 化学合成药(%) | 8.33 | - | 6.50 | - | 6.51 |
| 内部抵销(%) | -4.41 | - | -10.15 | - | -7.21 |
| 天然植物药系列(%) | 8.93 | - | 40.78 | - | 42.23 |
| 外购药品及医疗器械(%) | 85.76 | - | 56.71 | - | 56.61 |
| 妇科(%) | - | 4.85 | - | 5.04 | - |
| 骨科系列(%) | - | 1.72 | - | 1.29 | - |
| 抗疟疾类(%) | - | 1.44 | - | 1.67 | - |
| 消化系统(%) | - | 5.01 | - | 6.89 | - |
| 心脑血管疾病治疗领域(%) | - | 27.60 | - | 27.58 | - |
| 药品批发与零售(%) | - | 52.15 | - | 45.92 | - |
| 其他(%) | 1.39 | 7.23 | 6.16 | 11.60 | 1.87 |
| 毛利构成(%) | |||||
| 化学合成药(%) | 24.49 | - | 10.67 | - | 9.76 |
| 内部抵销(%) | -2.30 | - | -0.73 | - | -3.02 |
| 天然植物药系列(%) | 22.18 | - | 72.58 | - | 72.39 |
| 外购药品及医疗器械(%) | 52.35 | - | 16.61 | - | 19.61 |
| 妇科(%) | - | 7.12 | - | 6.30 | - |
| 骨科系列(%) | - | 3.52 | - | 2.19 | - |
| 抗疟疾类(%) | - | 1.46 | - | 0.95 | - |
| 消化系统(%) | - | 8.48 | - | 10.53 | - |
| 心脑血管疾病治疗领域(%) | - | 54.44 | - | 47.76 | - |
| 药品批发与零售(%) | - | 17.29 | - | 16.32 | - |
| 其他(%) | 3.28 | 7.69 | 0.88 | 15.96 | 1.27 |